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Abstract
Objective
We present an objective and quantitative approach for diagnosing internuclear oph-
thalmoplegia (INO) in multiple sclerosis (MS).
Methods
A validated standardized infrared oculography protocol (DEMoNS [Demonstrate Eye
Movement Networks with Saccades]) was used for quantifying prosaccades in patients withMS
and healthy controls (HCs). The versional dysconjugacy index (VDI) was calculated, which
describes the ratio between the abducting and adducting eye. The VDI was determined for peak
velocity, peak acceleration, peak velocity divided by amplitude, and area under the curve (AUC)
of the saccadic trajectory. We calculated the diagnostic accuracy for the several VDI parameters
by a receiver operating characteristic analysis comparing HCs and patients with MS. The
National Eye Institute Visual Function Questionnaire–25 was used to investigate vision-related
quality of life of MS patients with INO.
Results
Two hundred ten patients withMS and 58HCs were included. The highest diagnostic accuracy
was achieved by the VDI AUC of 15° horizontal prosaccades. Based on a combined VDI AUC
and peak velocity divided by amplitude detection, the prevalence of an INO inMS calculated to
34%. In the INO group, 35.2% of the patients with MS reported any complaints of double
vision, compared to 18.4% in the non-INO group (p = 0.010). MS patients with an INO had
a lower overall vision-related quality of life (median 89.9, interquartile range 12.8) compared to
patients without an INO (median 91.8, interquartile range 9.3, p = 0.011).
Conclusions
This study provides an accurate quantitative and clinically relevant deﬁnition of an INO in MS.
This infrared oculography-based INO standard will require prospective validation. The high
prevalence of INO in MS provides an anatomically well described and accurately quantiﬁable
model for treatment trials in MS.
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An internuclear ophthalmoplegia (INO) is an eye movement
disorder inmultiple sclerosis (MS) in which the adducting eye
movement is slowed down compared to the abducting eye
movement. The cause of an INO is demyelination in the
medial longitudinal fasciculus (MLF). The MLF connects the
abducens nucleus of one side of the brainstem with the ocu-
lomotor nucleus of the other side. Conjugacy of horizontal
saccades therefore depends on conduction through the MLF.
With clinical assessment, the diagnosis can be easily missed,1
and consequently no gold standard is available for diagnosis.
Infrared oculography is a noninvasive, objective, and quantitative
tool to assess an INO, which recently has become more widely
available. Earlier studies have established the versional dyscon-
jugacy index (VDI)2 as a sensitive way to describe an INO.3,4
However, the few studies that investigated VDI parameters in
patients with MS had important limitations, such as small sample
sizes and inclusion bias by subjective selection of patients with
a clinically evident INO.3–5 Furthermore, there was a lack of
a systematic approach to the analytical evaluation of the various
VDI parameters and cutoﬀ points.
The aim of this study was to provide prevalence ﬁgures of
INO in MS based on an objective and quantitative deﬁnition.
Next, we investigated the eﬀect of an INO on patients’ visual
functions and vision-related quality of life (QoL).
Methods
Standard protocol approvals, registrations,
and patient consents
This study (study number 2015.227) was approved by the
Medical Ethical Committee on Human Research of the
Amsterdam University Medical Centers (location VUmc).
Written informed consent was obtained from all participants
prior to inclusion.
Study design and patient population
For this observational cross-sectional study, patients with MS
and healthy controls (HCs) were included from the
Amsterdam MS cohort, an ongoing observational cohort of
the Amsterdam University Medical Center.6–8 For this co-
hort, eligible patients were prospectively recruited from our
MS Center. Participants were at least 18 years of age. All
patients with MS had to fulﬁll clinical and radiologic criteria
for a diagnosis of clinically deﬁnite MS.9 The disease course
was described as relapsing-remitting (RR), secondary
progressive, or primary progressive.10 Exclusion criteria in-
cluded immunodeﬁciency syndrome, relapse or course of
steroids within 6 weeks of inclusion, pregnancy, or history of
drug or alcohol abuse. HCs were recruited via advertisements
in the hospital and nonrelated family and friends.
Clinical and ophthalmologic assessment
All assessments (clinical, infrared oculography, and ques-
tionnaires) were performed on the same day and in the same
order of sequence.
The disease duration was calculated in years from the ﬁrst MS
symptom. The Expanded Disability Status Scale (EDSS)
score11 was determined by a certiﬁed examiner to assess the
level of disability. The global Multiple Sclerosis Severity
Score, which combines disease duration and EDSS in one
variable, was taken from the lookup table provided in refer-
ence 12. History of symptomatic MS-associated optic neuritis
(MSON) was based on a consensus protocol,13 including
recording of the best corrected high- and low-contrast visual
acuities (HCVA and LCVA, respectively) using Sloan letter
charts (100% for HCVA, 2.5% for LCVA).14 The vision-
related QoL was assessed with the National Eye Institute
Visual Function Questionnaire–25.15,16 In addition, an in-
house questionnaire for complaints speciﬁc to problems with
eye movement was included (available from Protocols.io
[Questionnaire Eye Movement Complaints] protocols.io/
view/questionnaire-eye-movements-complaints-vrxe57n).
Infrared oculography
The eye movements were measured using the EyeLink 1000
Plus eye tracker (SR Research, Ottawa, Canada), which uses
the pupil and corneal reﬂection for determining eye position.
Data were sampled at a frequency of 1,000 Hz. Participants
were seated at 92 cm (eye-monitor distance) in front of
a display monitor (HP EliteDisplay E241i, 24 inch, resolution
of 1,024 × 768 pixels used). The head was stabilized by means
of a chin and a forehead rest. The EyeLink 1000 Plus desktop
mount (with the camera) was located 50 to 55 cm in front of
the chin rest, just below the display monitor (ﬁgure 1A). All
experiments were performed in a quiet room under dim
lighting conditions (20–50 Lux). Proprietary built-in algo-
rithms were used for calibration and validation procedures.
We developed and validated a standardized protocol suitable for
a multicenter setting, the DEMoNS [Demonstrate Eye Move-
ment Networks with Saccades] protocol.17 The prosaccadic task
of this protocol was used for the present study. This assessment
Glossary
Am = saccadic amplitude; AUC = area under the curve; DEMoNS = Demonstrate Eye Movement Networks with Saccades;
EDSS = Expanded Disability Status Scale; FPA = ﬁrst-pass amplitude; HC = healthy control; HCVA = high-contrast visual
acuity; INO = internuclear ophthalmoplegia; IQR = interquartile range; LCVA = low-contrast visual acuity; MLF = medial
longitudinal fasciculus; MS = multiple sclerosis; MSON = multiple sclerosis–associated optic neuritis; Pv = peak velocity;
QoL = quality of life; ROC = receiver operating characteristic; RR = relapsing-remitting; VDI = versional dysconjugacy index.
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contains 5 trials of 12 horizontal prosaccades, from the center of
the screen to an eccentric location, either 8° or 15° left or 8° or 15°
right, in a random order and after a ﬁxation period with a random
duration between 1 and 3.5 seconds. The target of the mea-
surement is shown in ﬁgure 1B. Four examples of saccades of
patients with MS captured by infrared oculography are shown in
ﬁgure 1, D–G.
For the automatic and oﬄine analysis of the eye movement
data, we used an in-house written program in MATLAB
(MathWorks, Inc., Natick, MA).17 To pass quality control, at
least 50% of centrifugal saccades needed to be acceptable for
a participant to be included.
The mean VDI values were calculated for the following param-
eters: peak velocity (the maximum saccadic velocity during the
saccadic trajectory), peak acceleration (the maximum accelera-
tion during the saccadic trajectory), and ﬁrst-pass amplitude
(FPA) (ratio of the eye position when the abducting eye ﬁrst
reaches the target position5). Furthermore, we included 2 new
VDI parameters, the main sequence relationship (peak velocity
divided by saccadic amplitude [Pv/Am]) and the area under the
Figure 1Measurement with infrared oculography
(A) Setup of themeasurement. Participants were seated in front of a displaymonitor with their head stabilized with a chin and forehead rest. The camera was
located in front of the chin rest, just below the line of sight. (B) Target used in the measurements: circle with a black cross in the center. (C) Schematic
representation of the AUC. The AUC is assessed from the first starting saccade (left eye in red, right eye in blue) until the last ending saccade (left or right eye).
In this period, the area is calculated for both eyes separately by summing the horizontal eye position at every time pointminus the horizontal start position of
the saccade. (D–G) Horizontal eye position (y-axis) against the time (x-axis) of a leftward saccade of 4 different patients with multiple sclerosis, captured by
infrared oculography. The blue line represents the right eye; the red line represents the left eye. (D) Leftward saccade without adduction delay, VDI AUC 1.07
and VDI Pv/Am 1.00. (E) Leftward saccade with clear adduction delay, VDI AUC 1.60 and VDI Pv/Am 2.32. (F) Leftward saccade with mild adduction delay, VDI
AUC 1.37 and VDI Pv/Am of 1.15. (G) Leftward saccade with mild adduction delay, VDI AUC 1.12 and VDI Pv/Am of 1.25. AUC = area under the curve of the
saccadic trajectory; Pv/Am = peak velocity divided by amplitude; VDI = versional dysconjugacy index.
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curve (AUC) of the horizontal saccadic trajectory (ﬁgure 1C).
The VDI is a ratio of the abducting to the adducting eye move-
ment. The advantage of using the VDI instead of the primary
monocular parameters is that it eliminates the majority of the
within- and between-subject variability of these parameters. The
reproducibility of these VDI parameters is excellent with all
intraclass correlation coeﬃcients above 0.9.17 Mean VDI of
rightward saccades and mean VDI of leftward saccades were
added separately in the analysis.
Statistical analyses
In absence of a quantitative gold standard for an INO, we were
required to calculate reasonable cutoﬀ values. Our assumption
was that there was no pathologic INO in the asymptomatic
HCs. Therefore, we calculated a range of cutoﬀ points for the
various VDI parameters by a receiver operating characteristic
(ROC) analysis using HCs and patients with MS. Because the
only certain factor in this analysis is the expected absence of
INO inHCs, high speciﬁcity values are needed.We decided to
compare sensitivity of the individual parameters in the spec-
iﬁcity range above 97.5%, because a speciﬁcity of 97.5% is
analogous to the commonly used z score of >1.96 of a HC
group (1.96 is the value of the 97.5 percentile point of the
normal distribution). Subsequently, detection of the diﬀerent
parameters was compared. Based on the highest accuracy,
a VDI threshold or combination of VDI thresholds was picked
for detecting an INO. Next, patients with MS were di-
chotomized in a group with (INO group) and without (non-
INO group) INO. Finally, the adduction delay was used to
subclassify the INO group into bilateral, left, and right.
Data were analyzed visually and statistically for normality. In-
dependent t tests (gaussian data) and nonparametric tests
(nongaussian data) were used for the comparison of parameters
between patients with MS and HCs and between patients with
and without INO. The χ2 test was used for categorical data.
Logistic regression analyses were used to analyze the relationship
of presence of an INO inMS to diﬀerences in vision-relatedQoL
(lowest vs highest 2 tertiles). These analyses were adjusted for the
possible confounders age, sex, and EDSS score.
Statistical analyses were performed using SPSS Statistics 22.0
(IBM Corp., Armonk, NY). The visual comparisons of VDI
parameters were performed with Venny 2.1 (J.C. Oliveros,
bioinfogp.cnb.csic.es/tools/venny/index.html).
Data availability
Anonymized, General Data Protection Regulation–compliant
data can be shared by request from qualiﬁed investigators.
The protocol for measurement and analysis of eye move-
ments is available from Protocols.io.
Results
Study population
In total 226 patients with MS and 61 HCs were recruited to this
study. Of these, we had to exclude 16 patients with MS and 3
HCs because of corrupted data ﬁles (n = 6), quality of the data (n
= 12), and one mono-ocular measurement. The demographic
and clinical characteristics of the included participants are sum-
marized in table 1. The percentage of females in the patient group
was higher than in the HC group (p = 0.046). Patients had
a mean disease duration of 21.0 (±8.5) years and the majority
(62%) had an RR disease course.
INO detection
On average, 6.2 (±6.0) saccades per participant were excluded
based on automated quality control.
The raw data of the VDI AUC of 15° saccades (VDI AUC15)
is summarized in ﬁgure 2A. The left side of the graphs shows
a gaussian distribution of the VDI AUC15 in the HCs, with
a mean VDI AUC15 of 1.063 (±0.062). Based on ROC
analyses, a cutoﬀ value of 1.174 for the VDI AUC15 (hori-
zontal dotted line in ﬁgure 2B) gave the highest accuracy.
With this threshold, the speciﬁcity for separating HCs from
patients with MS was 98%.
This ROC-based analysis was systematically repeated for all
VDI parameters (except the VDI FPA). The cutoﬀ values for 3
levels of diagnostic speciﬁcity (100%, 99%, 98%) are summa-
rized in table 2; for nearly all parameters, the speciﬁcity level of
98% gave the highest accuracy. Comparisons between the VDI
parameters at a speciﬁcity level of 98% are shown in ﬁgure 3.
The total number of VDIs above the thresholds in theMS group
was higher for 15° (ﬁgure 3A) than for 8° saccades (ﬁgure 3B) at
this same speciﬁcity level. Furthermore, addition of the VDI Pv/
Am15 parameter (speciﬁcity level 98%, cutoﬀ 1.180; ﬁgure 2B)
to the detection with the VDI AUC15, the percentage of VDIs
above the threshold increased from 19% to 23%, with minimal
change of speciﬁcity (from 98% to 97%). This indicated that
using a combined detection of the VDI Pv/Am15 and VDI
AUC15 resulted in the highest accuracy. Therefore, for the
remainder of this study, an INO was diagnosed in a patient if at
least one of these VDIs exceeded the threshold.
An additional 12.7 (±8.3) saccades per measurement had to
be discarded when calculating the VDI FPA, which resulted in
exclusion of more than 50% of the saccades in 59 participants.
Therefore, this VDI was excluded from further analysis.
INO prevalence and MS characteristics
The VDI AUC15 and VDI Pv/Am15 (ﬁgure 2) were used to
dichotomize patients into INO and non-INO. In total, 71
patients (34%) withMS were classiﬁed as having an INO. The
INOwas bilateral in 26 (37%), to the right in 21 (30%), and to
the left in 24 (34%).
In table 1, diﬀerences in disease characteristics are shown in
the INO and non-INO groups. Patients with an INO had
a longer disease duration compared to patients without INO
(p = 0.006). Likewise, patients with an INO were more dis-
abled on the EDSS (p < 0.001) and the Multiple Sclerosis
Severity Score (p = 0.012) compared to patients without INO.
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The median diﬀerence in the Brainstem Functional System
Score of the EDSS was 1.0 (p = 0.005). Furthermore, an INO
was more frequent in patients with a progressive disease
course (primary progressive, secondary progressive)
compared to patients with an RR disease course (p = 0.006).
Finally, HCVA was slightly lower in the INO group (p =
0.003) and there were no signiﬁcant diﬀerences in LCVA or
MSON between the INO and non-INO groups.
Table 1 Demographic and clinical characteristics of the healthy controls and patients with MS
Patients with MS
Healthy controls (n = 58)All (n = 210) INO (n = 71) Non-INO (n = 139)
Sex, female, n (%) 142 (68) 40 (56) 102 (73) 31 (53)
Age, y 54.5 (±10.8) 56.7 (±9.7) 53.3 (±11.2) 52.4 (±9.1)
Disease duration, y 21.0 (±8.5) 23.5 (9.0) 19.8 (±8.0) NA
EDSS, median (IQR, total range) 3.5 (3.5, 0.0–8.5) 4.0 (3.0, 1.5–8.5) 3.5 (2.0, 0.0–8.0) NA
MSSS, median, (IQR, total range) 2.9 (3.2, 0.2–9.3) 3.4 (3.4, 0.5–9.3) 2.7 (2.7, 0.2–8.9) NA
Disease type, n (%)
RRMS 131 (62) 34 (48) 97 (70) NA
SPMS 56 (27) 29 (41) 27 (19) NA
PPMS 18 (9) 7 (10) 11 (8) NA
Unclassifiable 5 (2) 1 (1) 4 (3) NA
HCVA, mean ODSa 52.6 (±8.7) 50.1 (±9.2) 53.9 (±8.1) NA
LCVA, mean ODSb 26.4 (±11.4) 25.0 (±11.9) 27.1 (±11.2) NA
Optic neuritis, n %)c 94 (49) 33 (49) 61 (48) NA
Abbreviations: EDSS = Expanded Disability Status Scale; HCVA = high-contrast visual acuity; INO = internuclear ophthalmoplegia; IQR = interquartile range;
LCVA = low-contrast visual acuity; MS = multiple sclerosis; MSSS = Multiple Sclerosis Severity Score; NA = not applicable; ODS = right (OD) and left (OS) eye
combined; PPMS = primary progressive multiple sclerosis; RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary progressive multiple sclerosis.
INO = patients withMS and INObased on combined detection: either cutoff of 1.174 of the versional dysconjugacy index area under the curve of 15° saccades
or 1.180 of the versional dysconjugacy index peak velocity/saccadic amplitude of 15° saccades. Non-INO = patients with MS without INO.
a HCVA data missing for 16 patients.
b LCVA data missing for 56 patients.
c Optic neuritis information missing for 16 patients.
Figure 2 VDI distribution
Distribution of the VDI AUC and Pv/Am of 15° saccades of healthy controls and patients with MS. Both leftward and rightward VDIs are included. The INO
detection thresholds are indicated by the dashed lines. PatientswithMSwhohad VDIs above one of these thresholds (red-shaded areas) are classified as INO.
(A) VDI AUC, detection threshold 1.174. (B) VDI Pv/Am, detection threshold 1.180. AUC = area under the curve; INO = internuclear ophthalmoplegia; MS =
multiple sclerosis; Pv/Am = peak velocity divided by amplitude; VDI = versional dysconjugacy index.
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INO and visual complaints and vision-
related QoL
The prevalence of complaints on the eye movement ques-
tionnaire is shown in ﬁgure 4A. In the INO group, 35.2% of
the patients with MS reported visual complaints consisting of
diplopia compared to 18.4% in the non-INO group. Only 3
patients (1.4%) reported “severe” or “very severe” complaints
of diplopia; they were all classiﬁed as having an INO. Like-
wise, 49.3% of the patients with an INO reported complaints
of visually focusing stationary objects and 60.6% of visually
Table 2 Summary of the upper reference values (VDI cutoff) for detection of an INO in MS (MS INO+) based on receiver
operating characteristic analysis
Target amplitude, deg
Specificity 1.000 Specificity 0.991 Specificity 0.983
VDI cutoff MS INO+ VDI cutoff MS INO+ VDI cutoff MS INO+
VDI peak velocity
8 + 15 1.378 0.119 1.297 0.143 1.251 0.171
8 1.328 0.140 1.311 0.145 1.272 0.171
15 1.797 0.088 1.279 0.140 1.250 0.167
VDI peak acceleration
8 + 15 1.524 0.133 1.494 0.136 1.409 0.152
8 1.520 0.131 1.440 0.145 1.420 0.155
15 2.141 0.100 1.446 0.140 1.410 0.150
VDI AUC
8 + 15 1.245 0.148 1.227 0.157 1.210 0.171
8 1.284 0.145 1.256 0.162 1.250 0.164
15 1.240 0.126 1.182 0.178 1.174 0.190
VDI Pv/Am
8 + 15 1.240 0.083 1.189 0.148 1.178 0.157
8 1.227 0.121 1.222 0.121 1.197 0.130
15 1.775 0.060 1.197 0.167 1.180 0.179
Abbreviations: AUC = area under the curve of the saccadic trajectory; Deg = degrees of visual angle; INO = internuclear ophthalmoplegia; MS = multiple
sclerosis; Pv/Am = peak velocity divided by amplitude; VDI = versional dysconjugacy index.
MS INO+ = fraction of VDIs in the MS group that exceed the corresponding VDI cutoff for detection of INO.
Figure 3 VDI parameter comparisons
Venn diagram showing the (overlap between) the
detection of internuclear ophthalmoplegias with
different VDI parameters. For every parameter,
the number and percentage of VDIs in the multi-
ple sclerosis group that exceeded the VDI cutoffs
at a specificity level of 98% (table 2) are presented.
Both leftward and rightward VDIs are included. (A)
VDIs of 15° saccades. Total number of VDIs above
the thresholds: 100. The bold black line indicates
the combined detection of the VDI AUC and VDI
Pv/Am of 15° saccades, which resulted in the
highest accuracy. With this detection, 97% of the
number of VDIs above the threshold is included,
which corresponds to 23% of all VDIs of patients
with multiple sclerosis included in the analysis.
The corresponding specificity (percentage of VDIs
of healthy controls that do not exceed the
threshold) is 97%. (B) VDIs of 8° saccades. Total
number of VDs above the thresholds is 85. AUC =
area under the curve of saccadic trajectory; Pv/
Am = peak velocity divided by amplitude; VDI =
versional dysconjugacy index.
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focusing moving objects, compared to, respectively, 29.9%
and 29.9% of patients without an INO.
Patients with MS reported a median overall vision-related
QoL score of 91.4 (interquartile range [IQR] 10.6). The
lowest scores were seen on the subdomains general vision
(median 80.0, IQR 20.0) and driving (median 83.1, IQR
25.0). When investigating the eﬀect of having an INO on
vision-related QoL, it was shown that MS patients with an
INO had a lower overall vision-related QoL (median 89.9,
IQR 12.8) compared to patients without an INO (median
91.8, IQR 9.3; ﬁgure 4B). This diﬀerence was apparent at
diﬀerent subdomains, most prominently in the subdomains
distance activities, role diﬃculties, and driving (ﬁgure 4B).
Furthermore, of the patients with MS who scored in the lowest
tertile of the overall vision-related QoL score, 44.1% were
classiﬁed as having an INO. Logistic regression analysis
revealed a signiﬁcant eﬀect of the presence of an INO on the
overall vision-related QoL score with an odds ratio of 1.86
(95% conﬁdence interval 1.01–3.40, p = 0.045; table 3), in-
dicating that the odds of having low vision-related QoL is
almost twice as high for patients with INO compared to
patients without. Similar eﬀect sizes were shown with adjust-
ments for sex, disease duration, and EDSS score (table 3). A
similar pattern was found for the subdomain role diﬃculties.
For the subdomain driving, there was an increase in eﬀect size
after adjustments. The eﬀect of the presence of an INO on the
distance activities score was not signiﬁcant and the eﬀect size
decreased after adjustments (table 3). These ﬁndings were
independent from direction or severity (VDI level) of the INO.
Discussion
This study introduces a systematic, quantitative, infrared
oculography approach for deﬁnition of an INO in MS. The
data are based on the validated DEMoNS protocol suitable for
a multicenter setting with excellent levels of reproducibility
(intraclass correlation coeﬃcients >0.9) for the VDI param-
eters used in this study.17 The systematic assessment of
a range of parameters shows that the VDI AUC and VDI Pv/
Am are new and robust measures for determining an INO.
The found prevalence of 34% implies that there are enough
patients with an INO in MS to use INO as a well-deﬁned
model for testing treatment strategies.
Figure 4 Eye movement complaints and vision-related QoL
(A) Frequency of complaints (of any se-
verity) on the eye movement question-
naire of patients with and without INO. (B)
Vision-related QoL scores of patients with
and without INO. The overall score and
the scores of a few subdomains are
shown. INO = internuclear oph-
thalmoplegia; QoL = quality of life.
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The VDI AUC was developed against the theoretical back-
ground of the ocular dysconjugacy in INO. This consists of
the primary delay in adduction, the overshoot of the
abducting eye, and the subsequent converging eye movement
for achieving an aligned ﬁxation (or nonaligned if adduction is
limited). With the VDI AUC, we tried to describe as many
aspects of this pathologic saccadic movement as possible since
it describes the accumulated eﬀects of all 3 types of dyscon-
jugacy. The VDI peak velocity is mostly described in the
literature2–4 and resulted in comparable results regarding
speciﬁcity and sensitivity as the VDI AUC.
At ﬁrst glance it may seem that the VDI peak velocity, on
which we and others reported before,2–4,18 already covers the
essential pathologic feature (adduction delay). The limitation
is that the VDI peak velocity considers one moment in time.
At second glance, the VDI Pv/Am has the advantage of de-
scribing the main sequence relationship of saccades. The VDI
Pv/Am therefore provides a purer description of the diﬀer-
ence of saccadic behavior between the 2 eyes compared to the
VDI peak velocity. The VDI Pv/Am is also less vulnerable to
artifacts because of the elimination of small-amplitude dif-
ferences between the diﬀerent saccades and small calibration
diﬀerences between eyes. We have found that adding the VDI
Pv/Am parameter to the detection with the VDI AUC
resulted in an increased percentage of VDIs above the
thresholds, with only a minor decrement in speciﬁcity. This is
probably because these 2 parameters describe distinct features
of INOs, which was supported by our VDI comparison.
Furthermore, when investigating a conjoined INO detection
in which both VDI AUC15 and VDI Pv/Am15 have to sur-
pass their threshold (14% of VDIs, data not shown), the
resulting speciﬁcity in our dataset was 100% (no HC classiﬁed
as INO). Therefore, we think this detection could be con-
sidered if a higher level of speciﬁcity is desirable. The VDI
peak acceleration, although theoretically sound, discriminates
less presumably to higher variability both in HCs and patients
with MS. We would be hesitant to recommend using the VDI
FPA, as hypometric saccades cannot be used for the calcula-
tion of this parameter.
Previous studies reporting prevalence of INO in MS are
sparse; the described prevalence values are between 24% and
55%.19–22 However, these studies are based on clinical
examinations, outdated techniques, small sample sizes, and/
or populations that are not well described. In our study, we
found an increasing prevalence with a longer disease duration
and higher EDSS scores in patients with MS, which indicates
that INO prevalence depends on the speciﬁc characteristics of
the MS population that is investigated in a study.
In previous studies, z scores based on HCs were used for
determining the threshold of INO detection.4,5 Our approach
was in essence similar, because we also based our threshold on
a healthy control population. However, we did not choose
a predeﬁned z score but looked at diﬀerent high-speciﬁcity
levels to the corresponding sensitivity. This approach enables
direct comparison of diﬀerent VDI parameters and thresh-
olds. For almost every VDI parameter, the highest combina-
tion of sensitivity and speciﬁcity was found at a speciﬁcity level
of 0.983, which corresponds to a z score of 2.12. Designing
cutoﬀ points based on continuous parameters risks losing
more detailed information as it is reductionistic. More in-
depth physiologic studies, such as a “physiologic INO” and
Table 3 Results of vision-related quality of life
VFQ-25 component Logistic regression INO, β OR (95% CI) p Value
Overall score Crude 0.62 1.86 (1.01–3.40) 0.045
Adjusted model 1 0.65 1.92 (1.03–3.61) 0.042
Adjusted model 2 0.72 1.92 (1.01–3.66) 0.048
Distance activities score Crude 0.50 1.65 (0.86–3.16) 0.135
Adjusted model 1 0.39 1.48 (0.75–2.93) 0.264
Adjusted model 2 0.25 1.29 (0.63–2.62) 0.487
Driving score Crude 0.75 2.11 (1.02–4.38) 0.031
Adjusted model 1 1.02 2.76 (1.25–6.12) 0.012
Adjusted model 2 0.87 2.40 (1.09–6.44) 0.039
Role difficulties score Crude 0.73 2.08 (1.12–3.86) 0.020
Adjusted model 1 0.79 2.20 (1.15–4.21) 0.017
Adjusted model 2 0.78 2.19 (1.13–4.24) 0.021
Abbreviations: CI = confidence interval; INO = internuclear ophthalmoplegia; OR = odds ratio; VFQ-25 = Visual Function Questionnaire–25.
Logistic regression analysis demonstrating the association between presence of INO and the dichotomized vision-related quality-of-life overall score and 3
subscale scores (lowest tertile compared to the highest 2 tertiles). Crude = unadjusted model; adjusted model 1 = adjustment for sex and disease duration;
adjusted model 2 = adjustment for sex disease duration (Expanded Disability Status Scale).
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aging-related phenomena, will beneﬁt from the use of the
more detailed data presented in ﬁgure 2. More important,
other centers are strongly advised to establish and validate
their own cutoﬀ values when making use of our approach.
Various devices, even of the same manufacturer and setups,
can result in relevant diﬀerences in parameters.17
As abducting saccades are slightly faster and larger than adducting
saccades inmost HCs, themean VDI is expected to lie just above
unity.23 However, it has been shown that not all recording
techniques are able to pick up this subtle asymmetry to the same
extent, as is especially the case for electro-oculography.2,4,24,25
This study shows that high-frequency infrared oculography is
capable of detecting these small intraocular diﬀerences.
Even though infrared oculography devices are increasingly
commercially available, the costs of high-frequency devices such
as the EyeLink are one limitation of this technique. Furthermore,
some expertise is required in measurement and analysis. Our
analyst performing the measurements experienced a learning
curve for performing the measurement in our center, especially
for problem-solving during the calibration procedure. In addi-
tion, the development of a measurement protocol and software
routines for data analysis can provide even more challenging
obstacles. Therefore, we have made all of our measurement and
analysis protocols available as open source (protocols.io). Lastly,
an important limitation of the infrared oculography technique is
that the measurement is unreliable if patients cannot properly
ﬁxate the target during the calibration procedure. This can occur,
for example, in patients with a nystagmus or with substantial
ocular motor paresis. In these cases, the magnetic search coil
technique26,27 is still preferred. In our study, 4 such patients were
excluded based on quality-control criteria.
Visual complaints and vision-related QoL in patients with MS
who have INO have rarely been described in detail before. A
diﬃculty is that visual complaints in MS may have various
causes apart from oculomotor problems. However, this study
shows that despite a similar prevalence of MSON in both
groups, patients with INO do have more visual complaints
inﬂuencing daily functioning than patients without INO, in-
dependent of disease duration and (physical) disability. We
think that detecting (subclinical) INO with infrared oculog-
raphy can aid in clarifying misunderstood visual complaints in
patients with MS. More insight can be gained from longitu-
dinal assessments. This will be relevant for interrogating the
relevance of changes over time on presence and severity of
patients’ symptoms. Finally, our results are in line with other
studies that showed a relationship between eye movement
abnormalities and disease severity. Therefore, longitudinal
data will permit testing of the prognostic relevance of an INO
on a whole range of clinometric relevant variables.21,22,28
Furthermore, because the neuroanatomy of INO is clearly
described, quantiﬁcation of presence and severity of INO can
provide an opportunity to link neuroradiologic abnormalities
to speciﬁc clinical disabilities inMS.Moreover, eyemovement
measures in patients with INO could serve as a surrogate
outcome measure for nerve conduction in the MLF in ther-
apeutic trials. A case study in 2014 and a recent placebo-
controlled study showed that fampridine decreases the
adduction delay in patients with MS and INO, measured with
high-frequency infrared oculography.29,30
Because of the ease of measurement and the shown response
to therapy, INO is a promising model for testing remyelina-
tion strategies in MS clinical trials. For such future trials, this
systematic infrared oculography approach, using our accurate
and quantitative outcome measures, may be of value.
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